<DOC>
	<DOCNO>NCT01945593</DOCNO>
	<brief_summary>To continue evaluation safety efficacy prophylaxis BAX 855 prevention treatment bleed episode previously treat patient ( PTPs ) ( child adults 0 75 year age ) severe hemophilia A .</brief_summary>
	<brief_title>Phase 3b Continuation Study Safety Efficacy Prophylactic BAX 855 PTPs With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Main Participants BAX 855 study provide continuation study inform consent form ( ICF ) prior end study visit review consider participation continuation study . These participant complete additional screening assessment within 2 week previous study 's end study visit return study site within 6 week previous study end study visit confirm eligibility continuation study . BAX 855 naïve participant ≥ 12 year age enrol continuation study enrollment phase 2/3 pivotal study close . BAX 855 naïve participant &lt; 12 year age country pediatric PTP study conduct enrolled continuation study enrollment pediatric PTP study close . Participants come BAX 855 study continuation study , consider enrol complete procedure assessment End Study Visit previous BAX 855 study Participant and/or legal representative has/have voluntarily provide sign informed consent Participant 0 75 year age screen Participant male severe hemophilia A ( Factor VIII ( FVIII ) clot activity &lt; 1 % ) confirm central laboratory screening ( least 72hour washout period ) document FVIII clot activity &lt; 1 % ( confirmation require BAX 855 naïve participant ) Participant previously treat plasmaderived FVIII concentrate recombinant FVIII ≥150 document exposure day ( EDs ) Participant currently receive prophylaxis ondemand therapy FVIII Participant Karnofsky Lansky performance score ≥ 60 . Participant human immunodeficiency virus negative ( HIV ) ; HIV+ stable disease CD4+ count ≥ 200 cells/mm^3 , confirmed central laboratory screening . Participant hepatitis C virus negative ( HCV ) antibody PCR testing ( positive , antibody titer confirm PCR ) , confirmed central laboratory screening ; HCV+ chronic stable hepatitis . Participant willing able comply requirement protocol Main Participant detectable FVIII inhibitory antibody ( ≥ 0.4 Bethesda unit ( BU ) use Nijmegen modification Bethesda assay ) confirm central laboratory screening . Participant history FVIII inhibitory antibody ( ≥ 0.4 BU use Nijmegen modification Bethesda assay ≥ 0.6 BU use Bethesda assay ) time prior screening . Participant diagnose inherit acquire hemostatic defect hemophilia A ( eg , qualitative platelet defect von Willebrand 's disease ) . Participant known hypersensitivity towards mouse hamster protein , polyethylene glycol ( PEG ) , Tween 80 . Participant severe chronic hepatic dysfunction . Participant severe renal impairment . Participant current recent ( &lt; 30 day ) use PEGylated drug prior study participation schedule use drug study participation . Participant participate another clinical study involve investigational product ( IP ) BAX 855 device within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study . Participant medical , psychiatric , cognitive illness recreational drug/alcohol use , opinion investigator , would affect participant safety compliance . Participant family member employee investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>